Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
kmikesara, Have no idea why anyone would buy this stock since it is gonna be taken over by a large investor and the stock goes away. Just as the PR says if he calls in the loan and they can't pay it then he owns the company and all it's assets and the investors lose all their money.
carm, there are no bids on level 2 for .0101 except the standard 5000. Did you get your stock or pull your bid? You can buy all you want at .012.
carm as mybad has said make sure it's not AON. Also there could be millions of shares ahead of you at .0101. It goes by FIFO.
dirkie, but notice how there is a buyer there to pick up all the dumps.
Kgem, thanks for correcting the mistake, it also needs to come from the company.
They will probably want to change this paragraph.
CAVU has invested over $1.5 in the Chisholm lease and owns all of the improvements and has developed an integration of off the shelf technology that works great together," said William C. Robinson , President of CAVU Resources, Inc.
Sure hope they have invested more than a buck and a half.
If you notice I outlined that statement in my post in RED. I think it's all over for HEPI.
Liquidfan, tomorrow has come and gone...3 times.
MyBad.....yep mybad...LOL so Dirkie you only have 390K...OK go ahead and complain. When I put the decimal in the right place I own close to 10% of the old float. But in the perspective of stock portfolios 3.9 million shares of a penny stock is only $39K. I think that decimal is in the right place, just a tiny percent of most investors holdings. It's risk capital and this is a risk stock.
First of all the float is far more than 39+ million today. That number you quoted was from July.
Second if you own 3.9 million shares then why do you make such ridiculous statements in your posts. Is that the way one plays the market in Belgium, buy 3.9 million shares and then continually bad-mouth the stock?
dirkie,
You have 1% of the float (just what is the float today?) How about a straight answer...how many shares do you actually own. If you had 3-6 million shares I don't think you would post a message like this.
dirkie Member Profile
Monday, November 28, 2011 12:01:14 PM
Re: None
Post # of 9610
how many millions still to go? What a joke! But NO DILUTION hahaha!
If you need to ask that question you should not be in this stock.
dirke, English is not your first language so you probably do not understand tongue-in-cheek. I'm just messing with you.
just how many shares do you own. If I had to guess I would say it's a few thousand...so yes, by all means sell your shares and move on.
The shares outstanding are a little less than 200 million. At this time the authorized shares are 200 million. The estimated float in less than 60 million.
dirkie, actually it's over a billion and I'm going to buy 100 million shares today.
just torquing him up a little. No one knows how many more for sale.
dirkie, only 177 million more to go. Hang in there.
Hi Liquidfan, Happy TG to you as well. We had our grand-kids and great grand-kids down last weekend for early TG. We have dinner with my sister-in-laws family today and then another family dinner tomorrow. I think that will be enough turkey for us for the year. Good thing we have a gym membership, we are going to need it.
I guess one could say on the positive side they did report. Here's the highlight and low-lights.
We anticipate GRAS compliance by the end of the second quarter, 2012, at which time we expect to begin shipments under the contract. If we are unable to meet he GRAS standard (or NDI status), there will be a material adverse affect on our business, financial condition and results of operations.
Cost of Sales. Cost of Sales was $99,060 for the nine months ended September 30, 2011, as compared to $35,343 for the comparable prior period.
Research and Development Expenses. For the nine months ended September 30, 2011, we incurred $246,000 on research and development expenses, as compared to $294,053 for the comparable period in 2010. These expenses are mainly comprised of costs associated with external research. Our research and development costs declined de to our limited cash resources.. This research was initiated to further explore ProAlgaZyme?'s potential efficacy on the management of cholesterol levels. We have identified several potential bioactive compounds, but additional research aimed at isolating the compound further is expected to be completed during the fourth quarter of 2011.
Selling and Marketing Expenses. Selling and marketing expenses were $11,823 for the nine months ended September 30, 2011, as compared to $95,190 for the comparable prior period. The decrease in 2011 was due to the reclassification of wages paid to our Executive Vice President, combined with shifting available resources to research, resulting in our de-emphasizing marketing.
During the second quarter of 2011 we received orders for 15,000 bottles, and shipped approximately 6,600 bottles. The balance of this order is pending payment from the distributor. During the third quarter of 2011 we received orders for 4,354 bottles, and shipped approximately 4,400 bottles. We anticipate further orders in the near term, subject to the ability of Ceptazyme to remit payment as required under the terms of the contract.
We intend to continue to pursue clinical study of our product and, subject to the results of such testing, increase advertising in 2011, subject to availability of sufficient funding, which we do not currently have.
General and Administrative Expenses. General and administrative expense was $333,021 for the nine months ended September 30, 2011, as compared to $960,625 for the comparable prior period. The decrease in general and administrative expense during 2011 is due primarily to an approximate $530,000 decrease in administrative salaries, of which approximately $500,000 was in the form of stock based compensation, a non-cash expense, combined with a decrease of $45,000 in costs associated with our 2010 stockholders meeting , and a $50,000 decrease in our rent expense.
Professional and Consulting Expenses. Professional and consulting expense was $386,355 for the nine months ended September 30, 2011, as compared to $2,000,489 for the comparable prior period. The decrease in professional and consulting expense during 2011 is due primarily to a decrease in stock based compensation of approximately $1,500,000, and a decrease in legal fees of approximately $180,000, offset by an increase in accounting fees of approximately $49,000.
Our primary source of funds during the nine months ended September 30, 2011 was from the sale and issuance of equity securities as well as proceeds from the issuance of convertible debentures. We anticipate that our operations and costs through the 4th quarter of 2011 will be funded from the proceeds from private placements and warrant exercises as well as the issuance of new debentures. We have an immediate and urgent need for additional capital. If we are unable to raise the capital necessary to fund our continuing operations, we will not be able to continue as a going concern and you will suffer a total loss of your investment.
net loss of $1,322,815 for the nine months ended September 30, 2011.
uring the nine months ended September 30, 2011, we incurred negative cash flows from operations of $770,442. As of September 30, 2011, we had a working capital deficiency of $917,042 and a stockholders' deficiency of $1,297,214. Although we recently raised a limited amount of capital, we have an immediate and urgent need for additional capital.
In September 2011, we issued a Senior Secured Note in the principal amount of $100,000. This Note is secured by all our assets and is payable within ten days of the lender's written demand. We currently do not have the funds to repay this loan. If the lender demands payment and we are unable to raise the funds needed to repay the loan, the lender could foreclose on our assets, in which case you would suffer a total loss of your investment.
We estimate that we will require approximately $1,500,000 in cash over the next 12 months in order to fund our normal operations. In addition, we will require additional funding in the range of $500,000 to $1,000,000 to fund our research initiatives. Based on this cash requirement, we have an immediate and urgent need for additional funding. Historically, we have had great difficulty raising funds from external sources; however, we recently were able to raise a limited amount of capital from outside sources.
Quarterly Report. Amigo please highlight the positives.
21-Nov-2011
Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
The Securities and Exchange Commission ("SEC") encourages companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "project," or "continue" or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Critical Accounting Policies
The accompanying discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical experience and all available information. However, future events are subject to change, and the best estimates and judgments routinely require adjustment. US GAAP requires us to make estimates and judgments in several areas, including those related to recording various accruals, income taxes, the useful lives of long-lived assets, such as property and equipment and intangible assets, and potential losses from contingencies and litigation. We believe the policies discussed below are the most critical to our financial statements because they are affected significantly by management's judgments, assumptions and estimates.
Results of Operations for the nine months ended September 30, 2011 and 2010.
Net Sales. Net sales for the nine months ended September 30, 2011 were $88,587 as compared to $52,451 for the comparable prior period. These sales reflect principally revenues from the distribution of our ProAlgaZyme? product. The increase in our revenue for 2011 is due to our exclusive distributorship agreement with Ceptazyme, LLC to distribute our product. In the fourth quarter of 2010 we received an initial licensing fee payment of $255,000 under the terms of this exclusive distributorship agreement. We recognized $11,250 in revenue from this licensing fee during the first nine months of 2011.
Although we anticipate the realization of increasing revenues from our exclusive distributorship agreement with Ceptazyme, LLC, our ability to realize any such increased revenue is dependent upon the satisfaction of certain conditions, including our product's meeting the FDA's GRAS standard or receiving New Diet Ingredient ("NDI") status form the FDA, which we have not satisfied as of this date, though we are working on meeting the GRAS standard. The minimum payment provisions under the distributorship agreement have not been operative because we do not yet meet the GRAS standard. We anticipate GRAS compliance by the end of the second quarter, 2012, at which time we expect to begin shipments under the contract. If we are unable to meet he GRAS standard (or NDI status), there will be a material adverse affect on our business, financial condition and results of operations.
Throughout 2010 and 2011, we were adversely impacted by a shortage of funds which has severely impeded our ability to market, test and expand the production of our ProAlgaZyme? product. Although we signed an exclusive distribution agreement in September of 2010, we intend to explore additional potential marketing opportunities, consistent with the limitations placed upon us by our exclusive distribution agreement with Ceptazyme, LLC. We believe that our ability to generate sales of the ProAlgaZyme? product will depend upon, among other things, further characterization of the product, identification of its method of action and further evidence of its efficacy, as well as advertising.
The testing necessary to further characterize the product, identify its method of action and further substantiate its effectiveness is ongoing.
Cost of Sales. Cost of Sales was $99,060 for the nine months ended September 30, 2011, as compared to $35,343 for the comparable prior period. Cost of Sales represents primarily costs related to raw materials, labor and the laboratory and controlled production environment necessary for the growing of the algae cultures that constitute the source of the biological activity of the ProAlgaZyme? product, and for conducting the necessary harvesting and production operations in preparing the product for sale. The increase in cost of sales for 2011 is due to an increase in overall production, combined with additional costs incurred in bottling our product offsite until the improvements to our new warehouse facility are completed.
Research and Development Expenses. For the nine months ended September 30, 2011, we incurred $246,000 on research and development expenses, as compared to $294,053 for the comparable period in 2010. These expenses are mainly comprised of costs associated with external research. Our research and development costs declined de to our limited cash resources.. This research was initiated to further explore ProAlgaZyme?'s potential efficacy on the management of cholesterol levels. We have identified several potential bioactive compounds, but additional research aimed at isolating the compound further is expected to be completed during the fourth quarter of 2011.
Selling and Marketing Expenses. Selling and marketing expenses were $11,823 for the nine months ended September 30, 2011, as compared to $95,190 for the comparable prior period. The decrease in 2011 was due to the reclassification of wages paid to our Executive Vice President, combined with shifting available resources to research, resulting in our de-emphasizing marketing.
In the past we were only accustomed to nominal sales of our sole product, ProAlgaZyme. In September of 2010, we signed an exclusive distribution agreement to sell our product. This exclusive distribution agreement called for an initial licensing fee of $255,000 (received in October of 2010) and monthly orders which increase as our ability to produce product increases, subject to satisfaction of certain conditions, including satisfaction of the GRAS standard (or NDI status); we are still working on meeting GRAS. An initial order of $51,100 was received in December of 2010. Due to several delays in the design of new packaging, this order was shipped in full during the month of April, 2011. During the second quarter of 2011 we received orders for 15,000 bottles, and shipped approximately 6,600 bottles. The balance of this order is pending payment from the distributor. During the third quarter of 2011 we received orders for 4,354 bottles, and shipped approximately 4,400 bottles. We anticipate further orders in the near term, subject to the ability of Ceptazyme to remit payment as required under the terms of the contract. However, we do not expect the distributor to begin purchasing the minimums until we satisfy the FDA's GRAS standard (Note 11).
We intend to explore additional third party distribution channels for our product, consistent with the limitations placed upon us by our exclusive distribution agreement with Ceptazyme, LLC. The limit on our ability thus far to advertise our product (due in part to the need for additional testing) has had and, until we are able to advertise our product based upon the results of "class of compound" testing and identification of the bioactive ingredient, will continue to have, a material adverse effect on sales revenue and operating results. We intend to continue to pursue clinical study of our product and, subject to the results of such testing, increase advertising in 2011, subject to availability of sufficient funding, which we do not currently have.
General and Administrative Expenses. General and administrative expense was $333,021 for the nine months ended September 30, 2011, as compared to $960,625 for the comparable prior period. The decrease in general and administrative expense during 2011 is due primarily to an approximate $530,000 decrease in administrative salaries, of which approximately $500,000 was in the form of stock based compensation, a non-cash expense, combined with a decrease of $45,000 in costs associated with our 2010 stockholders meeting , and a $50,000 decrease in our rent expense.
Professional and Consulting Expenses. Professional and consulting expense was $386,355 for the nine months ended September 30, 2011, as compared to $2,000,489 for the comparable prior period. The decrease in professional and consulting expense during 2011 is due primarily to a decrease in stock based compensation of approximately $1,500,000, and a decrease in legal fees of approximately $180,000, offset by an increase in accounting fees of approximately $49,000.
Liquidity and Capital Resources
Historically, we have not generated any material revenues from operations and have been in a precarious financial condition. Our unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have had recurring losses from operations. Our primary source of funds during the nine months ended September 30, 2011 was from the sale and issuance of equity securities as well as proceeds from the issuance of convertible debentures. We anticipate that our operations and costs through the 4th quarter of 2011 will be funded from the proceeds from private placements and warrant exercises as well as the issuance of new debentures. We have an immediate and urgent need for additional capital. If we are unable to raise the capital necessary to fund our continuing operations, we will not be able to continue as a going concern and you will suffer a total loss of your investment.
As of November 18, 2011, we had a cash balance of approximately $40,000. We have had only limited revenue ($88,587 for the nine months ended September 30, 2011) and have incurred significant net losses since inception, including a net loss of $1,322,815 for the nine months ended September 30, 2011. Subject to our product's meeting the FDA's GRAS standard or receiving New Diet Ingredient ("NDI") status form the FDA (neither of which standards do we currently meet), the revenue guaranteed to us under the exclusive distribution agreement is expected to contribute significantly to funding our normal operations. However, we have, since inception, consistently incurred negative cash flow from operations. During the nine months ended September 30, 2011, we incurred negative cash flows from operations of $770,442. As of September 30, 2011, we had a working capital deficiency of $917,042 and a stockholders' deficiency of $1,297,214. Although we recently raised a limited amount of capital, we have an immediate and urgent need for additional capital.
During the nine months ended September 30, 2011, our operating activities used $770,442 in cash, a decrease of $523,518 from the comparable prior period. The approximate $520,000 decrease in cash used by operating activities was primarily attributable to the following (all of which are approximated): a $4.8 million decrease in net loss, a $388,000 increase in accrued payroll taxes expenses and accounts payable, partially offset by a $2.2 million decrease fair value adjustment of derivative liability (a noncash expense), a $1.6 million decrease in stocks and warrants issued for services (a noncash expense), a $203,000 decrease in finance costs paid with warrants, and a $550,000 decrease in obligations to issue common stock.
During the nine months ended September 30, 2011, our financing activities generated $819,692, a $476,420 decrease from the comparable prior period. The decrease in cash provided by financing activities was due primarily to a decrease in proceeds from sales of securities and convertible debt.
Although we raised a limited amount of capital during the first nine months of 2011, we continue to experience a severe shortage of capital, which is materially and adversely affecting our ability to run our business. As noted above, we have been largely dependent upon external sources for funding. We have in the past had great difficulty in raising capital from external sources.
Subject to our ability to meet the FDA's GRAS standard, which we do not yet meet, our exclusive distribution agreement should generate revenue to help cover at least a portion of our normal operating expenses; however we will still be reliant upon external financing for the continuation of our research program. With the leasing of our new manufacturing and office facilities, we anticipate being able to increase our production as necessary to meet the minimum requirements called for in our distribution agreement, subject to having sufficient capital, which we do not currently have.
In September 2011, we issued a Senior Secured Note in the principal amount of $100,000. This Note is secured by all our assets and is payable within ten days of the lender's written demand. We currently do not have the funds to repay this loan. If the lender demands payment and we are unable to raise the funds needed to repay the loan, the lender could foreclose on our assets, in which case you would suffer a total loss of your investment.
We estimate that we will require approximately $1,500,000 in cash over the next 12 months in order to fund our normal operations. In addition, we will require additional funding in the range of $500,000 to $1,000,000 to fund our research initiatives. Based on this cash requirement, we have an immediate and urgent need for additional funding. Historically, we have had great difficulty raising funds from external sources; however, we recently were able to raise a limited amount of capital from outside sources.
In addition, we have only limited product liability insurance. If a product claim were successfully made against us, there could be a material adverse effect on our financial condition given our liquidity and cash limitations.
Significant elements of income or loss not arising from our continuing operations
Except as set forth below, we do not expect to experience any significant elements of income or loss other than those arising from our continuing operation. For the nine months ended September 30, 2010, we recognized $2,223,991 of expenses for financial statement purposes based on the change in fair value of derivative liabilities.
Seasonality
Our product is directed to the improvement of the health of our consumers, and we do not expect that operating results will be affected materially by seasonal factors. In addition, ProAlgaZyme? is cultivated in a climate-controlled laboratory environment, not subject to seasonal growing effects or influences
Staffing
We have conducted all of our activities since inception with a minimum level of qualified staff. We currently do not expect a significant increase in staff.
Off-Balance Sheet arrangements
We have no off-balance sheet arrangements that would create contingent or other forms of liability.
Item 4
T. Controls and Procedures
Management's Report on Disclosure Controls and Procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and we necessarily were required to apply our judgment in evaluating the cost-benefit relationship of possible changes or additions to our controls and procedures.
As of September 30, 2011, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive/principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our principal executive/principal financial officer concluded that our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, are effective in enabling us to record, process, summarize and report information required to be included in our periodic SEC filings within the required time period.
Changes in Internal control Over Financial Reporting. There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
imgoingfishing, .0111, .011, .010, .005 it's all irrelevant if the company actually starts pumping 100 to 200 bpd. The majority of this board indicated they were in this for the long haul so the day to day week to week variations should not be that concerning to them. Down side risk a penny, upside gain a buck or more. You do the math.
Let's hope that they turn out to be "cheap share", one never knows in this market but, as your post states, oil certainly is one place to be at this time.
Kgem, You're welcom. It's probably not the Ihub uploader the photos where sent to me in a word document by a friend and not directly from Noah. They were in BMP format. In order to upload them I had to copy them to a photoshop program and save them as a Jpeg file. The program I use is Psuite. It's an old program and does not do a good job with BMP format. But at least those who have not seen them can get a general idea of what's going on. Just like you I added to my long term position last week.
It's always next week, next month, in a couple of months yata yata yata, we've just started.....never we have finished and here are the concrete results. How many testing labs have sucked money out of HEPI now???
I suggest any who are concerned about today's volume give Noah a call:
Tel: 973-507-6199
sahy, I replied to his post and asked specific questions of him in 2 other post. He has not replied to either post.
Kgem, if Billy cares nothing about the individual investor then why take the time, effort and money to put together an annual stock holders meeting and then take investors to the site; or to hire an IR person to answer our questions. Penny stock CEO's that care nothing about the investor do not hold annual meetings and are not accessible, either themselves or through an IR person.
Kgem
Willy, I am glad you responded to my post on the CAVR board. First, I am certainly not mad at CAVR. I also do not use this stock or this forum as my own personal playground to the detriment of most other investors - I am glad you came clean about your intentions, and your trading MO. My intentions are to make money, short term, long term.
As I have said before, and will continue to say, this stock is broken for the forseeable future, Why would you say that? What if the independent research report paints a great picture of an up and coming little oil company?
I watched what happened during the last two or three runs CAVR made, and an individual was very forthright about how they ruined those runs by dumping half or more of the daily volume each and every day at the bid or lower. What runs are you talking about???- this person makes money, while all others lose. This individual Who is this individual? now brags about owning millions of shares - I believe him. So investors should know that he will not allow this stock to go much beyond the low .02s for a very long time. why not?
If you are an investor in CAVR, and hope to break even on your average investment of .0250 cents or higher, you will likely be out of luck for weeks or perhaps months, Haven't we been saying all along that this is a LONG TERM PLAY and you will be very disappointed about the stocks performance.
Sorry to break the news people, but I would be less than honest to tell you otherwise.
Kgem,
You write:
the inaction of CAVR, and the destructive actions of some investors,
This is a penny stock. Didn't the company just hold an annual shareholders meeting and invite all share holders to come to Dallas for the meeting? Didn't they take shareholders to their site and show them what they are doing? Didn't they hire and IR person to keep investors informed as to what was going on. For a penny stock (most of which are just shells) I think that's quite a bit of action.
Not sure what you mean by "destructive actions of some investors". There are no investors in penny stocks. There are simply speculators and gamblers. I see nothing wrong with putting in bids to buy the stock at .011 getting executed and then selling at .013 or .014 (investing...making money). I own several million shares that are stashed away for any nice run that may happen but, at the same time, I have also been trading the stock. If you make $200 per transaction and trade the stock 5 times a week you make a grand a week. Not a life changer but a nice tidy little income. Of course this is only possible when large blocks show up. 200K shares at .011 is only $2200. 200K at .0125 is $2500 a nice $300 profit. One could have done that a couple of times today alone.
I see no reason to be mad at a little penny stock company that is doing everything it can to increase shareholder value. No they are not promoting the stock. No they are not making a deal with the vendor, but they have upgraded their equipment and are working very hard to begin pumping lot's of oil. If you believe in them and what they are doing then this is a great time to buy the stock and average down.
They have no control over what a vendor does when the stock the vendor accepted for payment of services goes off restriction and the vendor decides to sell it.
sorry dirkie, you are correct playing with penny stocks is not investing...it is speculating (even gambling if you prefer that term) but with CAVR I, as well as others, believe the risk/reward ratio is high enough that I am willing to throw 50-60K at the stock. You do realize that 52K is only 2,000 shares of MSFT. In that respect It is my belief that CAVR will be at .022 before MSFT reaches $53. Now if you bought CAVR on the Xp pump and paid .04-.06 for it you may have a little wait before you are whole.
dirkie, I understand that English is not your first language but just what part of my post to you do you not understand. The shares outstanding have not and are not being diluted by this vendor selling his formally restricted shares on the open market. The float has increased. The only way the stock can be diluted is if the company is currently issuing more shares, and we have been told that they are not.
If you watch level 2 and watch the trades you may be tempted to speculate that the last 500K transaction was the last hurrah for the Vendor. Not saying that it was just, pointing out one possible scenario. I know that there are a few investors that have bids in for a few hundred K at .0105 and .011. I believe they are just trying to pick up a few extra shares at what they hope will be rock bottom prices. There are also some large amounts for sale all the way up to .07.
dirkie, Why would you think this is a dump. What if I had an order in to buy 500,000 at .011 and the vendor (the one who needs to sell) decided to go ahead and sell his last 500,000 at the bid. The trade may be registered as a sell but it was, in all reality, a buy. Every trade has a buyer and a seller.
As for your dilution statement when restricted shares are given they are added to the companies "shares outstanding". When they are taken off of restriction status that does not mean there are more shares outstanding. Are there more shares in the float if the restricted shares are now sold on the open market...Yes. Let say that CAVR had 172m share outstanding and 50m in the float. Last year they issued 5 million shares to a vendor for some work he did for them. That 5 million was added to the outstanding shares at the time of issue (outstanding goes from 172 to 177) but were not on the open market and did not effect the float. Let's say now the shares come off of restriction and the vendor decides to sell. The float will be increased by the 5 million shares, which means there is now more stock available for trading. This does not effect the PE of the company and is not dilution but it does effect how many shares are available for trading.
Light sweet crude 98.28
http://www.cmegroup.com/trading/energy/crude-oil/light-sweet-crude.html
Hard to tell on a Holiday like Veterans day but the vendor could have kept selling today if he has any stock left. Banks and funds were not active but then CAVR is not traded by Banks and funds. Today looked good and I think there are a few more eyes on the stock now than in the past.